GRI Bio, Inc. Common Stock
GRIGRI Bio, Inc. is a biotechnology company focused on developing therapies targeting autoimmune and inflammatory diseases. The company leverages a proprietary platform to identify and develop novel biologics aimed at modulating immune responses, with an emphasis on improving patient outcomes in conditions with unmet medical needs.
Company News
GRI Bio participated in a virtual investor segment discussing its Phase 2a study interim biomarker data for Idiopathic Pulmonary Fibrosis, highlighting potential therapeutic advances in treating inflammatory and fibrotic diseases using NKT cell modulators.
Windtree Therapeutics, a biotechnology company, announced the appointment of Leanne Kelly to its board of directors. Ms. Kelly has significant public company executive experience and will serve as an independent director and chair of the audit committee.
GRI Bio, a biotechnology company, announced that the European Patent Office has issued a decision to grant a patent for its NKT cell modulator GRI-0803 and its library of over 500 proprietary compounds. The company is focused on developing treatments for inflammatory, fibrotic, and autoimmune diseases.
GRI Bio, a biotechnology company, announced the exercise of existing warrants and the issuance of new warrants. The company intends to use the proceeds for working capital and general corporate purposes.
GRI Bio, a biotechnology company, announced that it will participate in the Virtual Investor Lunch Break Series on July 17, 2024, where the CEO will provide a corporate overview and business outlook.
